← Eichor
Study identifier: NCT06230614 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Effect of Diluent Volume on Colistin Inhalation Therapy

Condition: Inhalation Pneumonia  ·  Sponsor: Fu Jen Catholic University

PhaseNA
Planned participants60
Who can joinAll sexes, 18 Years to 100 Years
Healthy volunteersNo

About this study

The aim of this study is to investigate the impact of different diluent volumes for the same dosage of colistin in mechanically ventilated respiratory patients receiving colistin inhalation therapy. The study aims to determine whether the diluent volume has an effect on clinical outcomes, including ICU length of stay, total hospitalization duration, duration of respiratory support within 28 days, mortality rates within 28 days and 90 days, as well as analyze the pharmacokinetic profile of colistin in blood and bronchoalveolar lavage fluid. Additionally, the study will evaluate the incidence of nebulizer malfunctions and blockages. The findings of this research will help identify the optimal diluent volume for colistin inhalation therapy in clinical practice.

This description comes directly from the study's public registry record.

Talk to the study team

Ke-Yun Chao, PhD  ·  +886-905-301-879  ·  C00152@mail.fjuh.fju.edu.tw

Always discuss trial participation with your own doctor first.

Locations (1)

Fu Jen Catholic University Hospital, Fu Jen Catholic UniversityNew Taipei City, TaiwanRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06230614